ARCH Venture Partners, one of the largest U.S. technology venture firms investing in the development of seed and early-stage advanced technology companies, today announced that its eighth venture fund closed with more than $400 million in subscriptions. ARCH Venture Fund VIII exceeded its $250 million subscription target by more than $150 million.
Last week we announced a significant new strategic investor in Sablono, a startup developing software for the construction industry. Sablono is one of six seed-stage investments we made last year. This little seed company has done very well: Three out of the six companies got externally funded, and we have another big A round on the way. Still, we are constantly discussing how we, as an early-stage fund, need to tackle seed.
Originally posted on Forbes
As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets. 2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000. Last week was the busiest single week – with eight IPOs – since February 2000. Over 120 life science companies have gone public since the beginning of last year.
A July 5th article in Crain’s Chicago, “Plant venture seeds with Midwest capital” claimed that all of the seeds are in place to make Chicago a hub of entrepreneurial innovation.
Illinois does have globally competitive universities; big corporations investing in innovation; a raft of business incubators and accelerator programs; serial entrepreneurs eager to mentor and mentoring programs to leverage this new pool of entrepreneurs; government partners willing to lend a hand; recognized Chicago-grown companies drawing investor interest and serving as a proving ground for young talent; and enthusiastic early stage investors who want to help founders develop their ideas.
The digital health space has continued to heat up, and it’s looking like 2014 will be a big year for investment in the space.
A new Rock Health report says that halfway through 2014 more than $2.2B has been invested in digital health startups. That’s already more than the $1.97 billion invested in the space during all of 2013, and 2013 was a record year for funding in the space.
The layoffs seen in the life sciences industry have been slightly offset, by a sharp rise medtech employment in Illinois – meaning job growth in the highly paid biosciences sector has remained generally steady among the nation’s many biotech clusters, according to a Battelle report released at the BIO International Conference.